363 related articles for article (PubMed ID: 34748820)
1. NOD2-mediated P2Y
Zhong H; Waresi M; Zhang W; Han L; Zhao Y; Chen Y; Zhou P; Chang L; Pan G; Wu B; Li J; Zhang S; Shi H; Luo X; Gao W; Qi Z; Ding Z
Biochem Pharmacol; 2021 Dec; 194():114822. PubMed ID: 34748820
[TBL] [Abstract][Full Text] [Related]
2. The Function and Regulation of Platelet P2Y12 Receptor.
Li X; Zhang G; Cao X
Cardiovasc Drugs Ther; 2023 Feb; 37(1):199-216. PubMed ID: 34319489
[TBL] [Abstract][Full Text] [Related]
3. Platelets Express Activated P2Y
Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
[TBL] [Abstract][Full Text] [Related]
4. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
Mshelbwala FS; Hugenberg DW; Kreutz RP
J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
[TBL] [Abstract][Full Text] [Related]
5. Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y
Brambilla M; Becchetti A; Rovati GE; Cosentino N; Conti M; Canzano P; Giesen PLA; Loffreda A; Bonomi A; Cattaneo M; De Candia E; Podda GM; Trabattoni D; Werba PJ; Campodonico J; Pinna C; Marenzi G; Tremoli E; Camera M
Arterioscler Thromb Vasc Biol; 2023 Oct; 43(10):2042-2057. PubMed ID: 37589138
[TBL] [Abstract][Full Text] [Related]
6. P2Y12 Receptor Modulates Sepsis-Induced Inflammation.
Liverani E; Rico MC; Tsygankov AY; Kilpatrick LE; Kunapuli SP
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):961-71. PubMed ID: 27055904
[TBL] [Abstract][Full Text] [Related]
7. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X
Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793
[TBL] [Abstract][Full Text] [Related]
8. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
Kimmelstiel C; Stevenson R; Nguyen N; Van Doren L; Zhang P; Perkins J; Kapur NK; Weintraub A; Castaneda V; Kuliopulos A; Covic L
Thromb Res; 2019 May; 177():59-69. PubMed ID: 30851630
[TBL] [Abstract][Full Text] [Related]
9. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis.
Zhang S; Zhang S; Hu L; Zhai L; Xue R; Ye J; Chen L; Cheng G; Mruk J; Kunapuli SP; Ding Z
Circulation; 2015 Mar; 131(13):1160-70. PubMed ID: 25825396
[TBL] [Abstract][Full Text] [Related]
11. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
[TBL] [Abstract][Full Text] [Related]
12. Thrombus remodelling by reversible and irreversible P2Y
Tunströmer K; Faxälv L; Larsson P; Lindahl TL; Boknäs N
Platelets; 2023 Dec; 34(1):2157805. PubMed ID: 36631918
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
[TBL] [Abstract][Full Text] [Related]
15. Platelet inhibition by P2Y
Shih CC; Chan MV; Kirkby NS; Vojnovic I; Mitchell JA; Armstrong PC; Warner TD
Br J Pharmacol; 2021 Dec; 178(23):4758-4771. PubMed ID: 34383973
[TBL] [Abstract][Full Text] [Related]
16. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Máchal J; Hlinomaz O
Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
[TBL] [Abstract][Full Text] [Related]
18. Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y
Wolska N; Boncler M; Polak D; Wzorek J; Przygodzki T; Gapinska M; Watala C; Rozalski M
Molecules; 2019 Dec; 25(1):. PubMed ID: 31905703
[TBL] [Abstract][Full Text] [Related]
19. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
20. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski JA; Zhou C; Winters KJ; Lachno DR; Howard J; Payne CD; Mant T; Jurcevic S; Frelinger AL
Platelets; 2015; 26(5):474-9. PubMed ID: 25140584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]